<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.113185</article-id><article-id pub-id-type="publisher-id">ACM-41266</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210300000_44151870.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  不同剂量右美托咪定对丙泊酚–芬太尼复合用于宫颈锥切术麻醉效果的影响
  Influence of Different Doses of Dexmedetomidine on the Anesthesia Effect of Propofol-Fentanyl Combined in Cervical Conization
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>蔡</surname><given-names>胜男</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>世端</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>贾</surname><given-names>媛芳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>米</surname><given-names>军桥</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>欢妮</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院麻醉科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>03</month><year>2021</year></pub-date><volume>11</volume><issue>03</issue><fpage>1294</fpage><lpage>1300</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：比较复合不同剂量右美托咪定在宫颈锥切术中对患者呼吸、循环及恢复时间的影响。方法：选择择期拟行宫颈锥切术的患者90例，ASA I~II级，年龄18~60岁，体重45~75 kg，BMI 18~28 kg∙m
   <sup>−2</sup>。按照随机数字表法将患者分为3组，每组30例。D1组、D2组和D3组分别于患者入室后静脉输注右美托咪定0.3、0.6、0.9 μg∙kg
   <sup>−1</sup>，泵注时间10 min。随后靶控输注丙泊酚(起始靶浓度1.5 μg∙mL
   <sup>−1</sup>)和静注芬太尼0.5 μg∙kg
   <sup>−1</sup>复合麻醉。观察并记录各时间点的心率(HR)、平均动脉压(MAP)、呼吸频率(RR)、呼吸末二氧化碳(P
   <sub>ET</sub>CO
   <sub>2</sub>)、丙泊酚效应室浓度(Ce)。记录丙泊酚及芬太尼用量，苏醒时间，恢复时间，不良反应，术后调查术者及患者的满意度。结果：由于影响手术操作，D1组3例患者使用了神级肌肉阻滞剂，排除在研究之外。与D1组相比，D2组患者术中P
   <sub>ET</sub>CO
   <sub>2</sub>和RR均无显著降低，呼吸维持稳定，MAP无显著降低，血流动力学稳定(P &lt; 0.05)。与D3组相比，D2组患者HR无显著降低，血流动力学稳定(P &lt; 0.05)。D1组舌后坠的发生率为51.9%，呼吸暂停发生率为18.5%，血压降低发生率为25.9%，D3组心动过缓发生率为73.3%，与D2组差异显著(P &lt; 0.05)。与D1组相比，D2及D3组丙泊酚和芬太尼用量减少(P &lt; 0.05)。三组患者苏醒时间无显著差异(P &gt; 0.05)，D2、D3组恢复时间更短(P &lt; 0.05)。三组手术时间、患者及术者的满意度无显著差异(P &gt; 0.05)。结论：与0.3 μg∙kg
   <sup>−1</sup>和0.9 μg∙kg
   <sup>−1</sup>的右美托咪定相比，0.6 μg∙kg
   <sup>−1</sup>右美托咪定减少了全麻药物的用量，提供了更稳定的呼吸和血流动力学特征，离室和恢复时间更短。
    Objective: To evaluate the effects of different doses of dexmedetomidine on respiration, circulation and recovery time during anesthesia in patients undergoing cervical conization. Methods: Ninety patients, ASA physical status I~II, aged 18~60 years, weighing 45~75 kg, BMI 18~28 kg∙m
   <sup>−2</sup>, undergoing cervical conization, were randomly divided into groups 0.3 μg∙kg
   <sup>−1</sup> (D1), 0.6 μg∙kg
   <sup>−1</sup> (D2), 0.9 μg∙kg
   <sup>−1</sup> (D3) using a random number table by nurse anesthetist (not participating in observation). Blind method was used in this study. Dexmedetomidine 0.3, 0.6, 0.9 μg∙kg
   <sup>−1</sup> were infused intravenously for 10 min before the patients are quiet in groups D1, D2, D3, respectively. And then TCI propofol (the target plasma concentration was set at 1.5 μg∙mL
   <sup>−1</sup>) and fentanyl 0.5 μg∙kg
   <sup>−1</sup> were given. The assessment of HR, MAP, RR, P
   <sub>ET</sub>CO
   <sub>2</sub>, Ce were continuously monitored. Dose of propofol and fentanyl, awakening time, recovery time, the incidence of adverse reaction were also recorded. Satisfaction of surgeons and patients were investigated after surgery. Results: Eighty-seven patients were enrolled, and three patients in group D1 were excluded from the study because of neuromuscular blocking agent use. P
   <sub>ET</sub>CO
   <sub>2</sub>, RR, MAP were not significantly lower in group D2 than in group D1, and respiratory was stable (P &lt; 0.05). HR was not significantly lower in group D2 than in group D3, and the patients were hemodynamically stable (P &lt; 0.05). The rate of glossocoma, apnea and hypotension is 51.9%, 18.5%, 25.9% respectively in group D1, the rate of bradycardia is 93.3% in group D3; there was significant difference with group D2 (P &lt; 0.05). Dose of propofol and fentanyl decreased in group D2 and D3 compared with group D1 (P &lt; 0.05). There was no significant difference in operative time, and the satisfaction rate of both patients and operators between the three groups (P &gt; 0.05). Conclusion: Compared with 0.3 and 0.9 μg&#183;kg
   <sup>−1</sup>, dexmedetomidine, 0.6 μg&#183;kg
   <sup>−1</sup> intravenous infusion reduced dosage of general anesthetic drugs, better kept the stability of respiration and circulation, and shortened the recovery time. 
  
 
</p></abstract><kwd-group><kwd>右美托咪定，自主呼吸，麻醉，宫颈锥切术, Dexmedetomidine</kwd><kwd> Automatic Respiratory</kwd><kwd> Anesthesia</kwd><kwd> Conization of Cervix</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：比较复合不同剂量右美托咪定在宫颈锥切术中对患者呼吸、循环及恢复时间的影响。方法：选择择期拟行宫颈锥切术的患者90例，ASA I~II级，年龄18~60岁，体重45~75 kg，BMI 18~28 kg∙m<sup>−2</sup>。按照随机数字表法将患者分为3组，每组30例。D1组、D2组和D3组分别于患者入室后静脉输注右美托咪定0.3、0.6、0.9 μg∙kg<sup>−1</sup>，泵注时间10 min。随后靶控输注丙泊酚(起始靶浓度1.5 μg∙mL<sup>−1</sup>)和静注芬太尼0.5 μg∙kg<sup>−1</sup>复合麻醉。观察并记录各时间点的心率(HR)、平均动脉压(MAP)、呼吸频率(RR)、呼吸末二氧化碳(P<sub>ET</sub>CO<sub>2</sub>)、丙泊酚效应室浓度(Ce)。记录丙泊酚及芬太尼用量，苏醒时间，恢复时间，不良反应，术后调查术者及患者的满意度。结果：由于影响手术操作，D1组3例患者使用了神级肌肉阻滞剂，排除在研究之外。与D1组相比，D2组患者术中P<sub>ET</sub>CO<sub>2</sub>和RR均无显著降低，呼吸维持稳定，MAP无显著降低，血流动力学稳定(P &lt; 0.05)。与D3组相比，D2组患者HR无显著降低，血流动力学稳定(P &lt; 0.05)。D1组舌后坠的发生率为51.9%，呼吸暂停发生率为18.5%，血压降低发生率为25.9%，D3组心动过缓发生率为73.3%，与D2组差异显著(P &lt; 0.05)。与D1组相比，D2及D3组丙泊酚和芬太尼用量减少(P &lt; 0.05)。三组患者苏醒时间无显著差异(P &gt; 0.05)，D2、D3组恢复时间更短(P &lt; 0.05)。三组手术时间、患者及术者的满意度无显著差异(P &gt; 0.05)。结论：与0.3 μg∙kg<sup>−1</sup>和0.9 μg∙kg<sup>−1</sup>的右美托咪定相比，0.6 μg∙kg<sup>−1</sup>右美托咪定减少了全麻药物的用量，提供了更稳定的呼吸和血流动力学特征，离室和恢复时间更短。</p></sec><sec id="s2"><title>关键词</title><p>右美托咪定，自主呼吸，麻醉，宫颈锥切术</p></sec><sec id="s3"><title>Influence of Different Doses of Dexmedetomidine on the Anesthesia Effect of Propofol-Fentanyl Combined in Cervical Conization</title><p>Shengnan Cai<sup>*</sup>, Shiduan Wang<sup>#</sup>, Yuanfang Jia, Junqiao Mi, Huanni Li</p><p>Department of Anesthesiology, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/68-1572073x5_hanspub.png" /></p><p>Received: Feb. 23<sup>rd</sup>, 2021; accepted: Mar. 11<sup>th</sup>, 2021; published: Mar. 29<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/68-1572073x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To evaluate the effects of different doses of dexmedetomidine on respiration, circulation and recovery time during anesthesia in patients undergoing cervical conization. Methods: Ninety patients, ASA physical status I~II, aged 18~60 years, weighing 45~75 kg, BMI 18~28 kg∙m<sup>−2</sup>, undergoing cervical conization, were randomly divided into groups 0.3 μg∙kg<sup>−1</sup> (D1), 0.6 μg∙kg<sup>−1</sup> (D2), 0.9 μg∙kg<sup>−1</sup> (D3) using a random number table by nurse anesthetist (not participating in observation). Blind method was used in this study. Dexmedetomidine 0.3, 0.6, 0.9 μg∙kg<sup>−1</sup> were infused intravenously for 10 min before the patients are quiet in groups D1, D2, D3, respectively. And then TCI propofol (the target plasma concentration was set at 1.5 μg∙mL<sup>−1</sup>) and fentanyl 0.5 μg∙kg<sup>−1</sup> were given. The assessment of HR, MAP, RR, P<sub>ET</sub>CO<sub>2</sub>, Ce were continuously monitored. Dose of propofol and fentanyl, awakening time, recovery time, the incidence of adverse reaction were also recorded. Satisfaction of surgeons and patients were investigated after surgery. Results: Eighty-seven patients were enrolled, and three patients in group D1 were excluded from the study because of neuromuscular blocking agent use. P<sub>ET</sub>CO<sub>2</sub>, RR, MAP were not significantly lower in group D2 than in group D1, and respiratory was stable (P &lt; 0.05). HR was not significantly lower in group D2 than in group D3, and the patients were hemodynamically stable (P &lt; 0.05). The rate of glossocoma, apnea and hypotension is 51.9%, 18.5%, 25.9% respectively in group D1, the rate of bradycardia is 93.3% in group D3; there was significant difference with group D2 (P &lt; 0.05). Dose of propofol and fentanyl decreased in group D2 and D3 compared with group D1 (P &lt; 0.05). There was no significant difference in operative time, and the satisfaction rate of both patients and operators between the three groups (P &gt; 0.05). Conclusion: Compared with 0.3 and 0.9 μg&#183;kg<sup>−1</sup>, dexmedetomidine, 0.6 μg&#183;kg<sup>−1</sup> intravenous infusion reduced dosage of general anesthetic drugs, better kept the stability of respiration and circulation, and shortened the recovery time.</p><p>Keywords:Dexmedetomidine, Automatic Respiratory, Anesthesia, Conization of Cervix</p><disp-formula id="hanspub.41266-formula61"><graphic xlink:href="//html.hanspub.org/file/68-1572073x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/68-1572073x8_hanspub.png" /> <img src="//html.hanspub.org/file/68-1572073x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>宫颈锥切术是诊治宫颈病变的常用术式，手术时间短，疼痛刺激轻微，麻醉要求患者宫颈松弛、不发生体动，术毕苏醒时间短。丙泊酚复合阿片类药物常用于该类手术的麻醉，但两种药物对于呼吸和循环均呈剂量依赖性抑制 [<xref ref-type="bibr" rid="hanspub.41266-ref1">1</xref>]，增加麻醉管理难度及安全隐患。右美托咪定为近年来用于临床的高选择性α2肾上腺素受体激动剂，通过作用于第四脑室旁的蓝斑核产生有效镇静，兼有镇痛效应，与全麻药物有协同作用，具有独特的呼吸抑制轻微的优势 [<xref ref-type="bibr" rid="hanspub.41266-ref2">2</xref>]。复合应用右美托咪定时可减少丙泊酚及阿片类药物的用量 [<xref ref-type="bibr" rid="hanspub.41266-ref3">3</xref>]，相应减轻对于呼吸、循环系统的影响，已被证实适用于不实施气管插管的麻醉 [<xref ref-type="bibr" rid="hanspub.41266-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.41266-ref5">5</xref>]。临床中应用右美托咪定的剂量范围较泛，无确切的优势剂量。有研究表明，输注负荷量1 μg∙kg<sup>−1</sup>右美托咪定患者心动过缓发生率明显增加 [<xref ref-type="bibr" rid="hanspub.41266-ref6">6</xref>]。因此，本研究以脑电双频指数(BIS)为麻醉镇静深度指标，通过比较1 μg∙kg<sup>−1</sup>以下的不同剂量右美托咪定应用于宫颈锥切术中对于患者呼吸、循环、恢复时间的影响，探讨保留自主呼吸的麻醉中更合适的右美托咪定剂量。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 一般资料</title><p>选择青岛大学附属医院2019年10月至2020年10月择期拟行子宫颈锥形切除术患者90例，ASA I~II级，年龄18~60岁，体重45~75 kg，体重指数18~28 kg∙m<sup>−</sup><sup>2</sup>，患者依从性好，自愿参加实验。排除标准：既往严重窦性心动过缓或房室传导阻滞等慢心律失常，高血压、冠心病等循环系统疾病患者，肝肾功异常患者，严重精神或神经疾病病史，长期服用镇静、镇痛药物，对研究药物有过敏史者。90例患者按照随机数字表法分为3组，每组30例患者，均由同一医生团队进行手术。本研究经青岛大学附属医院医学伦理委员会审核同意，患者及其家属签署知情同意书。</p></sec><sec id="s6_2"><title>2.2. 麻醉方法</title><p>患者均无术前用药。术前常规禁饮食8 h。入室后开放上肢静脉通路，输注乳酸钠林格液6 ml∙kg<sup>−</sup><sup>1</sup>。连接IntelliVue MP 80多功能监测系统(Philips公司，荷兰)，及该系统配备的脑电双频谱指数 M1034A 模块和ASPECT标准四电极传感器(Aspect 公司，美国)常规监测心电图(ECG)、心率(HR)、平均动脉压(MAP)、脉搏血氧饱和度(SpO<sub>2</sub>)及脑电双频指数(BIS)。使用该系统附带的M2526A经口/鼻吸氧装置及微流量CO<sub>2</sub>采样管监测呼吸频率(RR)和呼气末二氧化碳分压(P<sub>ET</sub>CO<sub>2</sub>)。患者安静平卧5 min后采集并记录上述监测参数为基础值。由非参与实验观察的麻醉科护士查看随机数字表，按照分组配置药物。D1、D2、D3组分别将右美托咪定(商品名艾贝宁，江苏恒瑞医药公司，规格为2 mL：200 μg，批号：1909020641) 0.3 μg∙kg<sup>−1</sup>、0.6 μg∙kg<sup>−1</sup>、0.9 μg∙kg<sup>−1</sup>用氯化钠注射液稀释成20 mL，均使用Graseby3100微量泵(Graseby公司，英国)以120 mL∙h<sup>−1</sup>的泵速静脉泵注10 min，随后三组均以0.1 μg∙kg<sup>−1</sup>泵注至手术开始20 min。三组右美托咪定注射液外观相似，容量相同。三组均使用Diprifusor靶控输注系统(Graseby 3500注射泵和TCI软件，Graseby公司，英国)输注1%丙泊酚(商品名：得普利麻，规格为50 mL：500 mg，意大利AstraZeneca公司，批号：RA164)，输入患者的年龄、体重，在右美托咪定输注5 min后以起始靶浓度1.5 μg∙mL<sup>−1</sup>启动TCI，根据患者BIS值调整靶控浓度(每次0.3 μg∙mL<sup>−1</sup>)，维持BIS值在50~60。静注芬太尼0.5 μg∙kg<sup>−1</sup>，手术消毒前再次静注0.5 μg∙kg<sup>−1</sup>，术中根据患者反映情况分次追加0.5 μg∙kg<sup>−1</sup>。开始手术时术者在宫颈周围以10 g∙L<sup>−1</sup>利多卡因(内含2.5 mg∙L<sup>−1</sup>肾上腺素) 40 mL阻滞浸润。手术放置油纱时停止泵注丙泊酚，TCI泵保留开机状态，继续记录丙泊酚效应室浓度。</p><p>术中持续吸氧3 L∙min<sup>−1</sup>，如出现呼吸抑制(RR &lt; 10次/min或SpO<sub>2</sub> &lt; 95%)或呼吸暂停，则通过放置口咽通气道或麻醉面罩实施辅助通气；出现心动过缓(HR &lt; 50次/min)，静注阿托品0.2 mg。出现低血压(MAP下降幅度超过基础值的30%)时，给予麻黄碱6 mg；高血压(MAP升高幅度超过基础值的30%)时，单次静注硝酸异山梨酯注射液(商品名：爱倍) 1 mg。</p></sec><sec id="s6_3"><title>2.3. 观察指标</title><p>记录入室安静5 min (T0)、泵注试验药物后(T1)、手术开始(T2)、术中10 min (T3)、术中20 min (T4)、术毕(T5)、呼之睁眼(T6)、离室(T7)各时间点的HR、MAP、RR、P<sub>ET</sub>CO<sub>2</sub>、丙泊酚c<sub>e</sub>。记录手术时间，丙泊酚及芬太尼用量，苏醒时间(停药至定向恢复，能准确回答问话)，恢复时间(入PACU至可安全返回病房)。记录不良反应(心动过缓、血压降低、舌后坠需放置通气道、呼吸抑制需辅助呼吸等)的例数，调查术者及患者的满意度。</p></sec><sec id="s6_4"><title>2.4. 统计分析</title><p>采用SPSS26.0统计学软件进行统计学分析。组内比较采用重复测量的方差分析，组间比较采用单因素方差分析，事后两两比较采用Bonferroni检验。计数资料比较采用χ<sup>2</sup>检验。以P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><p>实验共入选了87例择期行宫颈锥切术的患者。由于使用了神经肌肉阻滞剂，D1组三例患者排除在研究之外，D1组27例、D2组30例、D3组30例。</p><sec id="s7_1"><title>3.1. 一般情况和术中情况的比较</title><p>3组患者的年龄、体重、体重指数、手术时间、苏醒时间比较差异均无显著统计学意义(P &gt; 0.05)。3组恢复时间、丙泊酚总量、芬太尼总量差异显著(P &lt; 0.05)。见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of 3 groups who in general condition and intraoperative conditio</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >指标</th><th align="center" valign="middle" >D1组(n = 27)</th><th align="center" valign="middle" >D2组(n = 30)</th><th align="center" valign="middle" >D3组(n = 30)</th></tr></thead><tr><td align="center" valign="middle" >年龄/岁</td><td align="center" valign="middle" >39.7 &#177; 5.1</td><td align="center" valign="middle" >37.9 &#177; 8.0</td><td align="center" valign="middle" >40.4 &#177; 7.5</td></tr><tr><td align="center" valign="middle" >体重/kg</td><td align="center" valign="middle" >63.4 &#177; 6.2</td><td align="center" valign="middle" >62.1 &#177; 7.7</td><td align="center" valign="middle" >62.4 &#177; 5.3</td></tr><tr><td align="center" valign="middle" >体重指数/kg∙m<sup>−2</sup></td><td align="center" valign="middle" >22.3 &#177; 4.1</td><td align="center" valign="middle" >23.6 &#177; 3.0</td><td align="center" valign="middle" >23.3 &#177; 3.6</td></tr><tr><td align="center" valign="middle" >手术时间/min</td><td align="center" valign="middle" >26.0 &#177; 4.7</td><td align="center" valign="middle" >25.3 &#177; 6.0</td><td align="center" valign="middle" >26.8 &#177; 4.3</td></tr><tr><td align="center" valign="middle" >苏醒时间/min</td><td align="center" valign="middle" >9.3 &#177; 6.5</td><td align="center" valign="middle" >10.1 &#177; 5.5</td><td align="center" valign="middle" >9.7 &#177; 4.8</td></tr><tr><td align="center" valign="middle" >恢复时间/min</td><td align="center" valign="middle" >37.5 &#177; 8.1</td><td align="center" valign="middle" >17.3 &#177; 7.3<sup>a</sup></td><td align="center" valign="middle" >19.4 &#177; 10.2<sup>a</sup></td></tr><tr><td align="center" valign="middle" >丙泊酚总量/mg</td><td align="center" valign="middle" >341 &#177; 62</td><td align="center" valign="middle" >174 &#177; 50<sup>a</sup></td><td align="center" valign="middle" >171 &#177; 57<sup>a</sup></td></tr><tr><td align="center" valign="middle" >芬太尼总量/μg</td><td align="center" valign="middle" >150 &#177; 52</td><td align="center" valign="middle" >70 &#177; 23<sup>a</sup></td><td align="center" valign="middle" >68 &#177; 17<sup>a</sup></td></tr></tbody></table></table-wrap><p>表1. 3组患者一般情况和术中情况的比较 X &#175; &#177; S</p><p>D1：0.3 μg∙kg<sup>−</sup><sup>1</sup>右美托咪定组；D2：0.6 μg∙kg<sup>−1</sup>右美托咪定组；D3：0.9 μg∙kg<sup>−1</sup>右美托咪定组经单因素方差分析，两两比较：与D1组比较，<sup>a</sup>P &lt; 0.05；与D2组比较<sup>b</sup>P &lt; 0.05。</p></sec><sec id="s7_2"><title>3.2. 丙泊酚效应室浓度比较</title><p>D2和D3组T2至T7各点的丙泊酚效应室浓度均低于D1组，在T2至T5时间点具有统计学差异(P &lt; 0.05)。D3组与D2组无显著差异(P &gt; 0.05)。见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of effect compartment concentration of propofol in 3 groups at each time poin</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >T2</th><th align="center" valign="middle" >T3</th><th align="center" valign="middle" >T4</th><th align="center" valign="middle" >T5</th><th align="center" valign="middle" >T6</th><th align="center" valign="middle" >T7</th></tr></thead><tr><td align="center" valign="middle" >D1组(n = 27)</td><td align="center" valign="middle" >2.6 &#177; 0.3</td><td align="center" valign="middle" >2.3 &#177; 0.6</td><td align="center" valign="middle" >2 &#177; 0.5</td><td align="center" valign="middle" >1.3 &#177; 0.4</td><td align="center" valign="middle" >1.2 &#177; 0.2</td><td align="center" valign="middle" >1.2 &#177; 0.3</td></tr><tr><td align="center" valign="middle" >D2组(n = 30)</td><td align="center" valign="middle" >1.8 &#177; 0.4<sup>a</sup></td><td align="center" valign="middle" >1.3 &#177; 0.2<sup>a</sup></td><td align="center" valign="middle" >1.3 &#177; 0.4<sup>a</sup></td><td align="center" valign="middle" >1.0 &#177; 0.3<sup>a</sup></td><td align="center" valign="middle" >0.8 &#177; 0.4</td><td align="center" valign="middle" >0.8 &#177; 0.2</td></tr><tr><td align="center" valign="middle" >D3组(n = 30)</td><td align="center" valign="middle" >1.7 &#177; 0.4<sup>a</sup></td><td align="center" valign="middle" >1.2 &#177; 0.3<sup>a</sup></td><td align="center" valign="middle" >1.3 &#177; 0.4<sup>a</sup></td><td align="center" valign="middle" >0.8 &#177; 0.4<sup>ab</sup></td><td align="center" valign="middle" >0.8 &#177; 0.3</td><td align="center" valign="middle" >0.7 &#177; 0.2</td></tr></tbody></table></table-wrap><p>表2. 3组患者各时间点丙泊酚效应室浓度比较 X &#175; &#177; S，μg∙mL<sup>−1</sup></p><p>D1：0.3 μg∙kg<sup>−1</sup>右美托咪定组；D2：0.6 μg∙kg<sup>−1</sup>右美托咪定组；D3：0.9 μg∙kg<sup>−1</sup>右美托咪定组；T2：手术开始，T3：术中10 min，T4：术中20 min，T5：术毕，T6：呼之睁眼，T7：离室经单因素方差分析，两两比较：与D1组比较，<sup>a</sup>P &lt; 0.05；与D2组比较<sup>b</sup>P &lt; 0.05。</p></sec><sec id="s7_3"><title>3.3. 呼吸及血流动力学参数比较</title><p>与入室后基础值相比，D1组患者在手术开始时出现呼吸抑制，P<sub>ET</sub>CO<sub>2</sub>和RR均显著降低(P &lt; 0.05)，T3时P<sub>ET</sub>CO<sub>2</sub>显著增高(P &lt; 0.05)。与T0时相比，T1时D3组患者MAP时显著升高、HR显著减慢(P &lt; 0.01)。组间比较，T3、T4时刻D1组P<sub>ET</sub>CO<sub>2</sub>显著高于D2、D3组。见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of respiratory indexes and circulatory indexes in 3 groups at each time poin</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >时间</th><th align="center" valign="middle" >RR/次&#183;min<sup>−1</sup></th><th align="center" valign="middle" >P<sub>ET</sub>CO<sub>2</sub>/mmHg</th><th align="center" valign="middle" >HR/次&#183;min<sup>−1</sup></th><th align="center" valign="middle" >MAP/mmHg</th></tr></thead><tr><td align="center" valign="middle"  rowspan="8"  >D1组(n = 27)</td><td align="center" valign="middle" >T0</td><td align="center" valign="middle" >18.3 &#177; 2.1</td><td align="center" valign="middle" >37.3 &#177; 1.9</td><td align="center" valign="middle" >70.3 &#177; 10.1</td><td align="center" valign="middle" >80.3 &#177; 10.5</td></tr><tr><td align="center" valign="middle" >T1</td><td align="center" valign="middle" >17.0 &#177; 1.8</td><td align="center" valign="middle" >37.1 &#177; 1.1</td><td align="center" valign="middle" >65.2 &#177; 8.5<sup>a</sup></td><td align="center" valign="middle" >81.5 &#177; 7.9</td></tr><tr><td align="center" valign="middle" >T2</td><td align="center" valign="middle" >11.3 &#177; 1.0<sup>a</sup></td><td align="center" valign="middle" >28.7 &#177; 3.9<sup>a</sup></td><td align="center" valign="middle" >60.4 &#177; 9.1<sup>a</sup></td><td align="center" valign="middle" >66.4 &#177; 6.4<sup>a</sup></td></tr><tr><td align="center" valign="middle" >T3</td><td align="center" valign="middle" >12.7 &#177; 2.3<sup>a</sup></td><td align="center" valign="middle" >42.4 &#177; 2.5<sup>a</sup></td><td align="center" valign="middle" >59.2 &#177; 11.3<sup>a</sup></td><td align="center" valign="middle" >65.3 &#177; 5.9<sup>a</sup></td></tr><tr><td align="center" valign="middle" >T4</td><td align="center" valign="middle" >13.6 &#177; 3.1<sup>a</sup></td><td align="center" valign="middle" >45.6 &#177; 1.8<sup>a</sup></td><td align="center" valign="middle" >60.6 &#177; 5.8<sup>a</sup></td><td align="center" valign="middle" >67.5 &#177; 8.4<sup>a</sup></td></tr><tr><td align="center" valign="middle" >T5</td><td align="center" valign="middle" >13.0 &#177; 1.7<sup>a</sup></td><td align="center" valign="middle" >42.2 &#177; 1.3<sup>a</sup></td><td align="center" valign="middle" >60.4 &#177; 8.5<sup>a</sup></td><td align="center" valign="middle" >67.2 &#177; 7.2<sup>a</sup></td></tr><tr><td align="center" valign="middle" >T6</td><td align="center" valign="middle" >13.1 &#177; 2.4<sup>a</sup></td><td align="center" valign="middle" >38.1 &#177; 1.3</td><td align="center" valign="middle" >61.3 &#177; 9.3<sup>a</sup></td><td align="center" valign="middle" >70.7 &#177; 6.4<sup>a</sup></td></tr><tr><td align="center" valign="middle" >T7</td><td align="center" valign="middle" >13.8 &#177; 1.2<sup>a</sup></td><td align="center" valign="middle" >38.3 &#177; 1.2</td><td align="center" valign="middle" >61.5 &#177; 9.0<sup>a</sup></td><td align="center" valign="middle" >70.9 &#177; 6.3<sup>a</sup></td></tr><tr><td align="center" valign="middle"  rowspan="8"  >D2组(n = 30)</td><td align="center" valign="middle" >T0</td><td align="center" valign="middle" >19.1 &#177; 1.6</td><td align="center" valign="middle" >37.5 &#177; 1.5</td><td align="center" valign="middle" >68.4 &#177; 12.1</td><td align="center" valign="middle" >79.5 &#177; 10.3</td></tr><tr><td align="center" valign="middle" >T1</td><td align="center" valign="middle" >18.2 &#177; 2.0</td><td align="center" valign="middle" >36.7 &#177; 1.7</td><td align="center" valign="middle" >55.5 &#177; 7.6<sup>ab</sup></td><td align="center" valign="middle" >83.2 &#177; 6.9<sup>ab</sup></td></tr><tr><td align="center" valign="middle" >T2</td><td align="center" valign="middle" >15.0 &#177; 1.3<sup>ab</sup></td><td align="center" valign="middle" >33.6 &#177; 1.2<sup>ab</sup></td><td align="center" valign="middle" >52.8 &#177; 6.3<sup>ab</sup></td><td align="center" valign="middle" >72.4 &#177; 8.2<sup>ab</sup></td></tr><tr><td align="center" valign="middle" >T3</td><td align="center" valign="middle" >15.5 &#177; 2.6<sup>ab</sup></td><td align="center" valign="middle" >37.0 &#177; 1.9<sup>b</sup></td><td align="center" valign="middle" >55.3 &#177; 7.2<sup>ab</sup></td><td align="center" valign="middle" >72.3 &#177; 6.3<sup>ab</sup></td></tr><tr><td align="center" valign="middle" >T4</td><td align="center" valign="middle" >15.8 &#177; 3.0<sup>a</sup></td><td align="center" valign="middle" >37.0 &#177; 2.0<sup>b</sup></td><td align="center" valign="middle" >60.7 &#177; 10.0<sup>a</sup></td><td align="center" valign="middle" >75.7 &#177; 4.2<sup>b</sup></td></tr><tr><td align="center" valign="middle" >T5</td><td align="center" valign="middle" >15.7 &#177; 2.9<sup>ab</sup></td><td align="center" valign="middle" >36.2 &#177; 1.1<sup>b</sup></td><td align="center" valign="middle" >60.6 &#177; 7.5<sup>a</sup></td><td align="center" valign="middle" >76.2 &#177; 6.2<sup>b</sup></td></tr><tr><td align="center" valign="middle" >T6</td><td align="center" valign="middle" >16.3 &#177; 1.2<sup>ab</sup></td><td align="center" valign="middle" >36.6 &#177; 1.0</td><td align="center" valign="middle" >62.3 &#177; 9.1<sup>a</sup></td><td align="center" valign="middle" >78.4 &#177; 7.3<sup>b</sup></td></tr><tr><td align="center" valign="middle" >T7</td><td align="center" valign="middle" >16.4 &#177; 2.8<sup>ab</sup></td><td align="center" valign="middle" >36.6 &#177; 1.2</td><td align="center" valign="middle" >62.6 &#177; 9.2<sup>a</sup></td><td align="center" valign="middle" >78.5 &#177; 5.1<sup>b</sup></td></tr><tr><td align="center" valign="middle"  rowspan="8"  >D3组(n = 30)</td><td align="center" valign="middle" >T0</td><td align="center" valign="middle" >18.6 &#177; 1.5</td><td align="center" valign="middle" >36.9 &#177; 2.0</td><td align="center" valign="middle" >70.0 &#177; 9.3</td><td align="center" valign="middle" >80.4 &#177; 9.7</td></tr><tr><td align="center" valign="middle" >T1</td><td align="center" valign="middle" >17.5 &#177; 1.3</td><td align="center" valign="middle" >36.2 &#177; 1.5</td><td align="center" valign="middle" >50.4 &#177; 7.6<sup>abc</sup></td><td align="center" valign="middle" >89.7 &#177; 9.5<sup>abc</sup></td></tr><tr><td align="center" valign="middle" >T2</td><td align="center" valign="middle" >15.8 &#177; 1.9<sup>ab</sup></td><td align="center" valign="middle" >32.3 &#177; 2.5<sup>ab</sup></td><td align="center" valign="middle" >50.5 &#177; 12.0<sup>ab</sup></td><td align="center" valign="middle" >73.3 &#177; 6.3<sup>ab</sup></td></tr><tr><td align="center" valign="middle" >T3</td><td align="center" valign="middle" >15.4 &#177; 3.0<sup>ab</sup></td><td align="center" valign="middle" >36.8 &#177; 1.9<sup>b</sup></td><td align="center" valign="middle" >54.6 &#177; 6.5<sup>ab</sup></td><td align="center" valign="middle" >70.4 &#177; 6.5<sup>ab</sup></td></tr><tr><td align="center" valign="middle" >T4</td><td align="center" valign="middle" >15.7 &#177; 2.6<sup>ab</sup></td><td align="center" valign="middle" >37.6 &#177; 2.1<sup>b</sup></td><td align="center" valign="middle" >55.3 &#177; 9.1<sup>abc</sup></td><td align="center" valign="middle" >74.1 &#177; 7.3<sup>ab</sup></td></tr><tr><td align="center" valign="middle" >T5</td><td align="center" valign="middle" >15.1 &#177; 2.4<sup>ab</sup></td><td align="center" valign="middle" >37.8 &#177; 1.0<sup>b</sup></td><td align="center" valign="middle" >55.8 &#177; 7.0<sup>abc</sup></td><td align="center" valign="middle" >75.8 &#177; 9.2<sup>ab</sup></td></tr><tr><td align="center" valign="middle" >T6</td><td align="center" valign="middle" >15.2 &#177; 3.5<sup>ab</sup></td><td align="center" valign="middle" >36.7 &#177; 2.1</td><td align="center" valign="middle" >57.2 &#177; 8.3<sup>a</sup></td><td align="center" valign="middle" >77.3 &#177; 5.8<sup>a</sup></td></tr><tr><td align="center" valign="middle" >T7</td><td align="center" valign="middle" >15.3 &#177; 2.9<sup>ab</sup></td><td align="center" valign="middle" >36.0 &#177; 1.2</td><td align="center" valign="middle" >57.4 &#177; 8.2<sup>a</sup></td><td align="center" valign="middle" >78.2 &#177; 3.6<sup>a</sup></td></tr></tbody></table></table-wrap><p>表3. 3组患者术中各时间点呼吸指标及循环指标的比较 X &#175; &#177; S</p><p>D1：0.3 μg∙kg<sup>−1</sup>右美托咪定组；D2：0.6 μg∙kg<sup>−1</sup>右美托咪定组；D3：0.9 μg∙kg<sup>−1</sup>右美托咪定组；T0：入室安静5 min，T1：泵注试验药物后，T2：手术开始，T3：术中10 min，T4：术中20 min，T5：术毕，T6：呼之睁眼，T7：离室；RR：呼吸频率，P<sub>ET</sub>CO<sub>2</sub>：呼吸末CO<sub>2</sub>分压，HR：心率，MAP：平均动脉压经重复测量的方差分析，与T0比较，<sup>a</sup>P &lt; 0.05；经单因素方差分析，与D1组比较，<sup>b</sup>P &lt; 0.05，与D2组比较，<sup>c</sup>P &lt; 0.05。</p></sec><sec id="s7_4"><title>3.4. 满意度评分及不良反应</title><p>三组术者及患者满意度无显著差别(P &gt; 0.05)。D1组患者舌后坠、呼吸暂停、血压降低例数显著增多(P &lt; 0.05)，D3组心动过缓的病例数显著增加(P &lt; 0.05)。见表4。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Comparison of satisfaction and adverse reactions of patients and operators in 3 group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >指标</th><th align="center" valign="middle" >D1组(n = 27)</th><th align="center" valign="middle" >D3组(n = 30)</th><th align="center" valign="middle" >D3组(n = 30)</th></tr></thead><tr><td align="center" valign="middle" >术者满意度/分</td><td align="center" valign="middle" >9.5 &#177; 1.3</td><td align="center" valign="middle" >9.7 &#177; 1.3</td><td align="center" valign="middle" >9.7 &#177; 1.3</td></tr><tr><td align="center" valign="middle" >患者满意度/分</td><td align="center" valign="middle" >9.5 &#177; 1.2</td><td align="center" valign="middle" >9.6 &#177; 1.2</td><td align="center" valign="middle" >9.4 &#177; 1.0</td></tr><tr><td align="center" valign="middle" >舌后坠/[例(%)]</td><td align="center" valign="middle" >14 (51.9)</td><td align="center" valign="middle" >3 (10.0)<sup>a</sup></td><td align="center" valign="middle" >2 (6.7)<sup>a</sup></td></tr><tr><td align="center" valign="middle" >呼吸暂停/[例(%)]</td><td align="center" valign="middle" >5 (18.5)</td><td align="center" valign="middle" >1 (3.3)<sup>a</sup></td><td align="center" valign="middle" >0 (0.0)<sup>a</sup></td></tr><tr><td align="center" valign="middle" >心动过缓/[例(%)]</td><td align="center" valign="middle" >3 (11.1)</td><td align="center" valign="middle" >10 (33.3)<sup>a</sup></td><td align="center" valign="middle" >22 (73.3)<sup>ab</sup></td></tr><tr><td align="center" valign="middle" >血压降低/[例(%)]</td><td align="center" valign="middle" >7 (25.9)</td><td align="center" valign="middle" >1 (3.3)<sup>a</sup></td><td align="center" valign="middle" >1 (3.3)<sup>a</sup></td></tr></tbody></table></table-wrap><p>表4. 3组患者、术者满意度及不良反应比较</p><p>D1：0.3 μg∙kg<sup>−1</sup>右美托咪定组；D2：0.6 μg∙kg<sup>−1</sup>右美托咪定组；D3：0.9 μg∙kg<sup>−1</sup>右美托咪定组经χ<sup>2</sup>检验，与D1组比较，<sup>a</sup>P &lt; 0.05，与D2组比较，<sup>b</sup>P &lt; 0.05。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>宫颈锥切术是由外向内呈圆锥形切下一部分宫颈组织，由于女性的宫颈神经支配属于内脏神经系统，对疼痛不敏感，麻醉关注点主要抑制牵拉宫颈产生的不适感，通常不需要建立人工气道。气管插管全身麻醉固然能够满足手术要求，但由于手术时间短刺激小，过度的镇静易致术后恢复时间长，影响手术周转速度。于患者而言，不同的麻醉方式带来的费用也存在不小的差异。另有研究表明，与人工气道相比，维持自主呼吸能够提供更好的V/Q值和有效的肺泡通气 [<xref ref-type="bibr" rid="hanspub.41266-ref7">7</xref>]。本研究在维持BIS55 &#177; 5水平下，通过靶控输注丙泊酚复合芬太尼麻醉，比较了三种剂量的右美托咪定用于保持自主呼吸的宫颈锥切术患者中的呼吸状况和血流力学参数，以及离室时间和恢复时间。</p><p>本研究中三组术者和患者的满意度无明显差异，表明三种剂量均能安全有效的抑制手术刺激。与D1组相比，D2、D3组丙泊酚总量分别减少了49.0%和49.9%，芬太尼总量分别减少了53.3%、54.7%，证实了右美托咪定能够增强丙泊酚–芬太尼复合麻醉的效果，减少其用量。</p><p>在手术过程中，D1组右美托咪定由于剂量较小，需要复合相对大剂量的丙泊酚和芬太尼，患者呼吸频率明显降低，呼吸抑制率增加，导致高碳酸血症的出现。手术开始时(T2)已经泵注丙泊酚5 min，同时复合了一定剂量的芬太尼，出现呼吸幅度和频率的抑制，导致P<sub>ET</sub>CO<sub>2</sub>和RR降低。T3时刻开始P<sub>ET</sub>CO<sub>2</sub>剧烈升高，可能是由于先前P<sub>ET</sub>CO<sub>2</sub>偏低但血内二氧化碳分压仍处于偏高水平，从而刺激患者中枢化学感受器，将体内蓄积的CO<sub>2</sub>排出。实验中3例患者由于呼吸动度过大影响术者操作，给予肌肉阻滞剂置入喉罩控制气道。14例患者需要放置口咽通气道，其中5例需面罩手控呼吸。D2、D3组呼吸状况稳定，呼吸频率维持在基线水平，P<sub>ET</sub>CO<sub>2</sub>在30~40 mmHg之间。</p><p>D1组在输注丙泊酚和芬太尼后，血压降低，部分患者需要静注麻黄碱。表明0.3 μg∙kg<sup>−1</sup>的右美托咪定的血管收缩作用无法抵消全麻药物的循环抑制作用，与吴迷迷 [<xref ref-type="bibr" rid="hanspub.41266-ref8">8</xref>] 等的研究一致。D3组右美托咪定输注5 min时患者心率明显减慢、血压一过性增高，需要阿托品处理的例数远远超过其他两组，这是由于较大剂量的右美托咪定初期对于血管平滑肌的收缩引起的一过性血压升高作用，反射性引起心率减慢 [<xref ref-type="bibr" rid="hanspub.41266-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.41266-ref10">10</xref>]。而右美托咪定的抗交感作用会使心率进一步减慢，如不处理则引起严重后果，威胁患者安全。D2组心率稍减低但基本维持在50次/min以上，10例患者需处理，给予阿托品后心率即回升并保持稳定，与Pekka和Takayuki的 [<xref ref-type="bibr" rid="hanspub.41266-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.41266-ref12">12</xref>] 研究结果一致，表明合适剂量的右美托咪定输注一段时间后再输注丙泊酚和芬太尼，前者的血管收缩作用刚好抵消后者引起的降压作用，因此循环更加稳定。</p><p>术毕离室时间三组无明显差异。在PACU中，D1组恢复时间明显大于D2、D3组(P &lt; 0.05)，可能由于相对大剂量丙泊酚和阿片类药物的代谢残留。D3组恢复时间稍延长，但与D2组相比无统计学意义，与Maud的研究结论一致 [<xref ref-type="bibr" rid="hanspub.41266-ref13">13</xref>]。另有研究表明，小儿患者使用负荷剂量4 μg∙kg<sup>−</sup><sup>1</sup>的右美托咪定不会增加气道不良事件的发生率，可提供适当的镇静深度和良好的支气管镜异物取出条件 [<xref ref-type="bibr" rid="hanspub.41266-ref14">14</xref>]，故单次给予1 μg∙kg<sup>−</sup><sup>1</sup>以下右美托咪定不会影响患者恢复时间。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，复合应用右美托咪定0.6 μg∙kg<sup>−1</sup>能够明显增强丙泊酚芬太尼用于宫颈锥切术中的麻醉效果，且呼吸抑制轻微，血流动力学稳定，术后恢复时间短。本研究不足有以下两点：一是样本量较少；二是术者在宫颈周围注射局麻药物时，其中混合的肾上腺素对循环的影响大小尚未可知，我们将在以后的临床工作中进一步研究，论证本文结论。</p></sec><sec id="s10"><title>文章引用</title><p>蔡胜男,王世端,贾媛芳,米军桥,李欢妮. 不同剂量右美托咪定对丙泊酚–芬太尼复合用于宫颈锥切术麻醉效果的影响Influence of Different Doses of Dexmedetomidine on the Anesthesia Effect of Propofol-Fentanyl Combined in Cervical Conization[J]. 临床医学进展, 2021, 11(03): 1294-1300. https://doi.org/10.12677/ACM.2021.113185</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41266-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Kunisawa, T., Ueno, M., Kurosawa, A., et al. (2011) Dexmedetomidine Can Stabilize Hemodynamics and Spare Anesthetics before Cardiopulmonary Bypass. Journal of Anesthesia, 2, 818-822.  
&lt;br&gt;https://doi.org/10.1007/s00540-011-1215-3</mixed-citation></ref><ref id="hanspub.41266-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Gregory, B., Hammer, M.D., Bridget, M., Philip, M.D., Alan, R., Schroeder, M.D., et al. (2005) Prolonged Infusion of Dexmedetomidine for Sedation Following Tracheal Resection. Pediatric Anesthesia, 15, 616-620.  
&lt;br&gt;https://doi.org/10.1111/j.1460-9592.2005.01656.x</mixed-citation></ref><ref id="hanspub.41266-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Peden, C.J., Cloote, A.H., Stratford, N., et al. (2001) The Effect of Intravenous Dexmedetomidine Premedication on the Dose Requirement of Propofol to Induce Loss of Consciousness in Patients Receiving Alfentanil. Anaesthesia, 56, 408-413. &lt;br&gt;https://doi.org/10.1046/j.1365-2044.2001.01553.x</mixed-citation></ref><ref id="hanspub.41266-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">欧阳利华, 冯芳. 用右美托咪定对接受靶控输注丙泊酚静脉麻醉的宫腔镜手术患者进行辅助麻醉的效果[J]. 当代医药论丛, 2020, 18(8): 46-47.</mixed-citation></ref><ref id="hanspub.41266-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">阎玮, 袁莉, 王世端, 江岩, 高鲜丽, 刘少艳. 右美托咪定复合丙泊酚在宫颈锥切手术麻醉中的应用[J]. 中国新药与临床杂志, 2012, 31(4): 206-209.</mixed-citation></ref><ref id="hanspub.41266-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Kakkar, A., Tyagi, A., Nabi, N., et al. (2016) Comparison of Clonidine and Dexmedetomidine for Attenuation of Laryngoscopy and Intubation Response—A Randomized Controlled Trial. Journal of Clinical Anesthesia, 33, 283-288. &lt;br&gt;https://doi.org/10.1016/j.jclinane.2016.04.026</mixed-citation></ref><ref id="hanspub.41266-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Hemmings, H.C. and Hopkins, P.M. (2006) Foundations of Anaesthesia: Basic Sciences for Clinical Practice, 2nd Edition, Elsevier Mosby, 573-581.</mixed-citation></ref><ref id="hanspub.41266-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">吴迷迷, 王世端, 夏婧, 柳国强, 梁永新. 不同剂量右美托咪定对冠状动脉搭桥术患者麻醉诱导期间血流动力学的影响[J]. 临床麻醉学杂志, 2018, 34(9): 882-885.</mixed-citation></ref><ref id="hanspub.41266-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Ayse, M., Rauf, G., Ibrahim, E., et al. (2010) Premedication with Dexmedetomidine Alone or Together with 0.5% Lidocaine for IVRA. Musculoskeletal, 164, 242-247. &lt;br&gt;https://doi.org/10.1016/j.jss.2009.03.005</mixed-citation></ref><ref id="hanspub.41266-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Weerink Maud, A.S., Struys Michel, M.R.F., Hannivoort Laura, N., et al. (2017) Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine. Clinical Pharmacokinetics, 56, 893-913.  
&lt;br&gt;https://doi.org/10.1007/s40262-017-0507-7</mixed-citation></ref><ref id="hanspub.41266-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Pekka, T., Errol, L. and Ronald, B. (2003) Systemically Administered Alpha2-Agonist-Induced Peripheral Vasoconstriction in Humans. Anesthesiology, 99, 65-70. &lt;br&gt;https://doi.org/10.1097/00000542-200307000-00014</mixed-citation></ref><ref id="hanspub.41266-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Takayuki, K., Osamu, N., Michio, N., et al. (2009) Dexmedetomidine Suppresses the Decrease in Blood Pressure during Anesthetic Induction and Blunts the Cardiovascular Response to Tracheal Intubation. Journal of Clinical Anesthesia, 21, 194-199.</mixed-citation></ref><ref id="hanspub.41266-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Weerink, M.A.S., Struys, M.M.R.F., Hannivoort, L.N., et al. (2017) Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine. Clinical Pharmacokinetics, 56, 893-913. &lt;br&gt;https://doi.org/10.1007/s40262-017-0507-7</mixed-citation></ref><ref id="hanspub.41266-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Cai, Y., Li, W. and Chen, K. (2013) Efficacy and Safety of Spontaneous Ventilation Technique Using Dexmedetomidine for Rigid Bronchoscopic Airway Foreign Body Removal in Children. Pediatric Anesthesia, 23, 1048-1053.  
https://doi.org/10.1111/pan.12197</mixed-citation></ref></ref-list></back></article>